Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Emery

Showing results (221-230 of 229) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 229 results.
Plos One|September 18, 2015
Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor LineagesAnupama Reddy, Joseph D Growney, Nick S Wilson, et al.
Plos One|January 6, 2016
Correction: Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor LineagesAnupama Reddy, Joseph D Growney, Nick S Wilson, et al.
Science Translational Medicine|December 22, 2021
Genetic analysis of praziquantel response in schistosome parasites implicates a transient receptor potential channelWinka Le Clec'h, Frédéric D Chevalier, Ana Carolina A Mattos, et al.
Plos Pathogens|October 26, 2019
Oxamniquine resistance alleles are widespread in Old World Schistosoma mansoni and predate drug deploymentFrédéric D Chevalier, Winka Le Clec'h, Marina McDew-White, et al.
International Journal for Parasitology. Drugs and Drug Resistance|March 22, 2026
TRPtracker: a community database for monitoring praziquantel sensitivity at TRPM<sub>PZQ</sub> variantsClaudia M Rohr, Sang-Kyu Park, Kelsilandia Aguiar-Martins, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
TRPtracker: a community database for monitoring praziquantel sensitivity at TRPM <sub>PZQ</sub> variantsClaudia M Rohr, Sang-Kyu Park, Kelsilandia Aguiar-Martins, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Plos One|November 20, 2009
Profiling critical cancer gene mutations in clinical tumor samplesLaura E MacConaill, Catarina D Campbell, Sarah M Kehoe, et al.
Nature|November 26, 2010
COT drives resistance to RAF inhibition through MAP kinase pathway reactivationCory M Johannessen, Jesse S Boehm, So Young Kim, et al.
Pageof 23

Showing results (221-230 of 229) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 229 results.
Plos One|September 18, 2015
Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor LineagesAnupama Reddy, Joseph D Growney, Nick S Wilson, et al.
Plos One|January 6, 2016
Correction: Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor LineagesAnupama Reddy, Joseph D Growney, Nick S Wilson, et al.
Science Translational Medicine|December 22, 2021
Genetic analysis of praziquantel response in schistosome parasites implicates a transient receptor potential channelWinka Le Clec'h, Frédéric D Chevalier, Ana Carolina A Mattos, et al.
Plos Pathogens|October 26, 2019
Oxamniquine resistance alleles are widespread in Old World Schistosoma mansoni and predate drug deploymentFrédéric D Chevalier, Winka Le Clec'h, Marina McDew-White, et al.
International Journal for Parasitology. Drugs and Drug Resistance|March 22, 2026
TRPtracker: a community database for monitoring praziquantel sensitivity at TRPM<sub>PZQ</sub> variantsClaudia M Rohr, Sang-Kyu Park, Kelsilandia Aguiar-Martins, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
TRPtracker: a community database for monitoring praziquantel sensitivity at TRPM <sub>PZQ</sub> variantsClaudia M Rohr, Sang-Kyu Park, Kelsilandia Aguiar-Martins, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Plos One|November 20, 2009
Profiling critical cancer gene mutations in clinical tumor samplesLaura E MacConaill, Catarina D Campbell, Sarah M Kehoe, et al.
Nature|November 26, 2010
COT drives resistance to RAF inhibition through MAP kinase pathway reactivationCory M Johannessen, Jesse S Boehm, So Young Kim, et al.
Pageof 23